Article Trunk



Posts Tagged ‘biotechnology’

Living algae facades cover buildings, ******* in CO2 and sun to produce renewable energy

12.02.2020 · Posted in Technology Articles

The world's first bio-reactive facade, where glass panels cultivate microalgae to produce renewable energy, was unveiled on a residential building in Hamburg, Germany in 2013.  Since then, the technology has significantly improved, making the fa... ...

Scribe Therapeutics launches a platform for engineering CRISPR-based therapeutics

A new company called Scribe Therapeutics founded by two former members of CRISPR pioneer Jennifer Doudna’s UC Berkely genetics lab (alongside Doudna herself) launched on Tuesday, debuting a platform designed specifically to help develop and engineer new thereapeutics based on CRISPR for addressing specific diseases, with permanent treatments in patients. Doudna is part of the ...

Does early-stage health tech need more ‘patient’ capital?

Crista Galli Ventures, a new early-stage health tech fund in Europe, officially launched last week. The firm offers “patient capital” — with only a single LP (the Danish family office IPQ Capital) — and promises to provide portfolio companies with deep healthcare expertise and the extra runway needed to get over regulatory and efficacy hurdles ...

Zymergen raised $300 million because synthetic biology is so hot right now

Zymergen, one of the companies that’s developing biomanufacturing technologies which could reshape any number of industries, said it has raised $300 million in financing yesterday. It’s part of a wave of biotech companies that TechCrunch covered in depth last month. Synthetic biology startups are giving investors an appetite The investment total, announced yesterday, includes Series ...

Synthetic biology startups are giving investors an appetite

There’s a growing wave of commercial activity from companies that are creating products using new biological engineering technologies. Perhaps the most public (and tastiest) example of the promise biomanufacturing holds is Impossible Foods . The meat replacement company whose ground plants (and bioengineered additives) taste like ground beef just raised another $200 million earlier this ...

Atomwise’s machine learning-based drug discovery service raises $123 million

With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in ...

Jane Metcalfe, co-founder NEO.LIFE, has a cool upcoming book

Kevin Kelly and I interviewed our friend Jane Metcalfe for the Cool Tools podcast. Jane is the founder of NEO.LIFE, a media and events company tracking how digital tools and an engineering mindset are transforming human biology. Prior to that, she made chocolate on a pier ...

Luna is a new kind of space company helping biotech find its footing in microgravity

Toronto-based startup Luna Design and Innovation is a prime example of the kind of space company that is increasingly starting up to take advantage of the changing economics of the larger industry. Founded by Andrea Yip, who is also Luna’s CEO, the bootstrapped venture is looking to blaze a trail for biotechnology companies who stand ...

You’ve heard of CRISPR, now meet its newer, savvier cousin CRISPR Prime

CRISPR, the revolutionary ability to snip out and alter genes with scissor-like precision, has exploded in popularity over the last few years and is generally seen as the standalone wizard of modern gene-editing. However, it’s not a perfect system, sometimes cutting at the wrong place, not working as intended and leaving scientists scratching their heads. ...

UK biotech startup Mogrify injects $16M to get novel cell therapies to market soon

Cambridge, UK-based biotech startup Mogrify, which is working on systematizing the development of novel cell therapies in areas such as regenerative medicine, has closed an initial $16 million Series A. The raise follows a $4M seed in February — taking its total raised to date to $20M. Put simply, Mogrify’s approach entails analysis of vast ...